Literature DB >> 28636769

Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?

Jasmine Turna1,2, Beth Patterson1,3, Michael Van Ameringen1,3,4.   

Abstract

Anxiety and related disorders are the most common mental conditions affecting the North American population. Despite their established efficacy, first-line antidepressant treatments are associated with significant side effects, leading many afflicted individuals to seek alternative treatments. Cannabis is commonly viewed as a natural alternative for a variety of medical and mental health conditions. Currently, anxiety ranks among the top five medical symptoms for which North Americans report using medical marijuana. However, upon careful review of the extant treatment literature, the anxiolytic effects of cannabis in clinical populations are surprisingly not well-documented. The effects of cannabis on anxiety and mood symptoms have been examined in healthy populations and in several small studies of synthetic cannabinoid agents but there are currently no studies which have examined the effects of the cannabis plant on anxiety and related disorders. In light of the rapidly shifting landscape regarding the legalization of cannabis for medical and recreational purposes, it is important to highlight the significant disconnect between the scientific literature, public opinion, and related policies. The aim of this article is to provide a comprehensive review of the current cannabis treatment literature, and to identify the potential for cannabis to be used as a therapeutic intervention for anxiety, mood, and related disorders. Searches of five electronic databases were conducted (PubMed, MEDLINE, Web of Science, PsychINFO, and Google Scholar), with the most recent in February 2017. The effects of cannabis on healthy populations and clinical psychiatric samples will be discussed, focusing primarily on anxiety and mood disorders.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  anxiety disorders; cannabis treatment; depression; endocannabinoids; marijuana

Mesh:

Substances:

Year:  2017        PMID: 28636769     DOI: 10.1002/da.22664

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  24 in total

1.  Characteristics of Canadians likely to try or increase cannabis use following legalization for nonmedical purposes: a cross-sectional study.

Authors:  Harman S Sandhu; Laura N Anderson; Jason W Busse
Journal:  CMAJ Open       Date:  2019-06-14

Review 2.  Cannabis Legalization and College Mental Health.

Authors:  Ludmila De Faria; Lillian Mezey; Aaron Winkler
Journal:  Curr Psychiatry Rep       Date:  2021-03-03       Impact factor: 5.285

3.  Cannabis Legalization and Psychiatric Disorders: Caveat "Hemp-tor".

Authors:  Tony P George; Kevin P Hill; Franco J Vaccarino
Journal:  Can J Psychiatry       Date:  2018-02-26       Impact factor: 4.356

Review 4.  Gambling and Cannabis Use: Clinical and Policy Implications.

Authors:  Ken C Winters; James P Whelan
Journal:  J Gambl Stud       Date:  2020-03

5.  Cannabis Use and Prospective Long-Term Association with Anxiety: A Systematic Review and Meta-Analysis of Longitudinal Studies: Usage du cannabis et association prospective à long terme avec l'anxiété: une revue systématique et une méta-analyse d'études longitudinales.

Authors:  Siqi Xue; M Ishrat Husain; Haoyu Zhao; Arun V Ravindran
Journal:  Can J Psychiatry       Date:  2020-09-10       Impact factor: 4.356

6.  Cannabis and Depression.

Authors:  Daniel Feingold; Aviv Weinstein
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Medical and non-medical marijuana use in depression: Longitudinal associations with suicidal ideation, everyday functioning, and psychiatry service utilization.

Authors:  Amber L Bahorik; Stacy A Sterling; Cynthia I Campbell; Constance Weisner; Danielle Ramo; Derek D Satre
Journal:  J Affect Disord       Date:  2018-07-17       Impact factor: 4.839

8.  Pain Profiles among Young Adult Cannabis Users: An Analysis of Antecedent Factors and Distal Outcomes.

Authors:  Janna Ataiants; Ekaterina V Fedorova; Carolyn F Wong; Ellen Iverson; Jeffrey I Gold; Stephen E Lankenau
Journal:  Subst Use Misuse       Date:  2021-04-21       Impact factor: 2.164

9.  Gaps in evidence for the use of medically authorized cannabis: Ontario and Alberta, Canada.

Authors:  Cerina Lee; Jessica M Round; Scott Klarenbach; John G Hanlon; Elaine Hyshka; Jason R B Dyck; Dean T Eurich
Journal:  Harm Reduct J       Date:  2021-06-08

10.  Cannabidiol use and effectiveness: real-world evidence from a Canadian medical cannabis clinic.

Authors:  Lucile Rapin; Rihab Gamaoun; Cynthia El Hage; Maria Fernanda Arboleda; Erin Prosk
Journal:  J Cannabis Res       Date:  2021-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.